Skip to main content

Table 7 The correlation between CSC marker levels in sera with clinicopathological features and laboratory results in late stage CCA patients

From: Overexpression of a panel of cancer stem cell markers enhances the predictive capability of the progression and recurrence in the early stage cholangiocarcinoma

VariablesLate stage (TNM stage III, IV)
nCD44pCD44v6pCD44v8-10pEpCAMp
Sex
 Female240.51 ± 0.16 0.80 ± 0.15 0.71 ± 0.12 0.50 ± 0.17 
 Male430.52 ± 0.120.5840.78 ± 0.140.5730.70 ± 0.120.9400.47 ± 0.130.435
Age (year)
 Less than 61320.51 ± 0.12 0.80 ± 0.12 0.69 ± 0.10 0.46 ± 0.14 
 61 or greater350.52 ± 0.140.7690.78 ± 0.160.6510.71 ± 0.130.5050.50 ± 0.160.289
Tumor site
 Intrahepatic380.50 ± 0.13 0.77 ± 0.15 0.70 ± 0.11 0.46 ± 0.12 
 Extrahepatic290.54 ± 0.130.2310.82 ± 0.130.1280.71 ± 0.130.5390.50 ± 0.170.259
Histology type
 Papillary290.51 ± 0.14 0.78 ± 0.15 0.70 ± 0.12 0.47 ± 0.17 
 Others380.53 ± 0.130.5990.80 ± 0.140.5100.71 ± 0.120.8090.49 ± 0.130.562
Tumor marker
 CA19-9 (U/mL)
  < 37130.47 ± 0.14 0.79 ± 0.13 0.71 ± 0.13 0.44 ± 0.13 
  ≥ 37330.53 ± 0.130.1520.80 ± 0.160.8280.70 ± 0.110.8410.48 ± 0.130.257
 CEA (ng/mL)
  < 2.560.51 ± 0.20 0.71 ± 0.19 0.71 ± 0.10 0.52 ± 0.09 
  ≥ 2.5370.51 ± 0.110.8880.80 ± 0.130.1710.69 ± 0.100.5980.44 ± 0.110.108
 AFP (IU/mL)
  < 5330.52 ± 0.14 0.79 ± 0.16 0.70 ± 0.11 0.46 ± 0.11 
  ≥ 540.45 ± 0.200.3570.77 ± 0.110.7920.61 ± 0.060.1180.38 ± 0.110.199
Liver function test
 Direct bilirubin (mg/dL)
  < 1.5390.50 ± 0.14 0.77 ± 0.16 0.70 ± 0.11 0.46 ± 0.13 
  ≥ 1.5170.56 ± 0.120.1370.85 ± 0.090.0290.71 ± 0.110.6320.51 ± 0.140.227
 Total bilirubin (mg/dL)
  < 2.5350.49 ± 0.14 0.76 ± 0.16 0.68 ± 0.11 0.46 ± 0.13 
  ≥ 2.5210.55 ± 0.120.0890.85 ± 0.110.0370.73 ± 0.110.1490.51 ± 0.130.181
 ALT (U/L)
  < 40280.49 ± 0.14 0.76 ± 0.16 0.70 ± 0.12 0.48 ± 0.14 
  ≥ 40280.54 ± 0.120.1480.83 ± 0.130.0910.70 ± 0.110.9460.47 ± 0.120.708
 AST (U/L)
  < 40250.49 ± 0.15 0.75 ± 0.18 0.68 ± 0.11 0.45 ± 0.12 
  ≥ 40310.54 ± 0.120.1500.83 ± 0.110.0370.72 ± 0.110.1870.49 ± 0.140.295
 ALP (U/L)
  < 130190.47 ± 0.13 0.74 ± 0.16 0.65 ± 0.11 0.41 ± 0.11 
  ≥ 130370.54 ± 0.130.0560.82 ± 0.130.0490.72 ± 0.110.0240.51 ± 0.130.006
  1. CD44 cluster of differentiation 44, CD44v CD44 variant, EpCAM epithelial cell adhesion molecules, TNM primary tumor-node-metastasis, CA19-9 cancer antigen 19-9, CEA carcinoembryonic antigen, AFP alpha-fetoprotein, ALT alanine aminotransferase, AST aspartate aminotransferase, ALP: alkaline phosphatase